1. Scrip

Shilpa Medicare’s Plan For Eylea Biosimilar Spells Ambition, But Path Not Easy

Humira Biosimilar Trial Recruiting

 
• By Vibha Ravi

Shilpa Medicare’s plan for trials of an Eylea biosimilar shows the company’s ambition to leapfrog to a biosimilars-led growth strategy, one that Indian majors like Cipla and Lupin pivoted to post a successful generics program. However, the path isn’t going to be easy and Biocon/Viatris, Samsung Biologics are ahead

Arrow being aimed at man flying with arrow in hand
Shilpa's Biosimilars Ambitions Could Face Obstacles • Source: Alamy

Shilpa Medicare Ltd, a fledgling compared to Cipla Limited, Lupin Limited and Zydus Lifesciences Limited, has started its biosimilars program much before in its life cycle than these companies, which embarked on biosimilars journeys after achieving a certain scale in their generics business.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Trump’s Tariffs Add To European Warning Of $100bn US Exodus

 
• By Andrew McConaghie

European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.

Will Irish Eyes Still Be Smiling When Trump Tariffs Hits Pharma?

 
• By Kevin Grogan

The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.

China Deal-Making Matures As Foreign Partners Derisk Asset Acquisition

 
• By Xu Hu

Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.